Learn More
BACKGROUND The hurdle of cost effectiveness for the selection and reimbursement of drugs in Australia limits access to new medicines based on an assessment of cost relative to clinical benefit. Those drugs that are expensive and provide modest benefits will be less likely to receive a government price subsidy. There is concern that the cost-effectiveness(More)
BACKGROUND Little is known about the relative importance that oncologists attribute to the benefits and harms of anti-cancer drugs when considering treatment options with their patients. AIM To quantify the trade-offs made between overall survival, progression-free survival and adverse effects. METHODS A web-based survey elicited importance weights for(More)
BACKGROUND The PLATO (Platelet Inhibition and Patient Outcomes) randomized trial (NCT00391872) in patients with acute coronary syndromes (ACS) reported that ticagrelor (in addition to aspirin) reduced the rate of the composite end point of myocardial infarction (MI), stroke, or cardiovascular death compared with clopidogrel (in addition to aspirin) by 16%(More)
BACKGROUND Around the world government agencies responsible for the selection and reimbursement of prescribed medicines and other health technologies are considering how best to bring community preferences into their decision making. In particular, community views about the distribution or equity of funding across the population. These official committees(More)
BACKGROUND Australians access anticancer drugs predominantly through the Pharmaceutical Benefits Scheme (PBS). AIM To determine why the Pharmaceutical Benefits Advisory Committee (PBAC) rejects submissions to list anticancer drugs on the PBS. METHODS We reviewed publicly available information about submissions made to the PBAC for PBS listing of(More)
  • 1